Slide 1: Company Overview
Company Overview NYSE MKT: CRMD August 2013
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Th
Slide 3: CorMedix: A Catheter Care Company
CorMedix: A Catheter Care Company
Slide 4: Neutrolin catheter lock solution
| ¥CorMedix + Anantimicrobial/anticoagulant Catheter Lock Solution (CLS) specifically designed for: > Prevention of Catheter Related Neu rolin® Bloodstream Infections (CRBI) » Maintenance of catheter patency > Prevention of the formation of biofilm
Slide 5: Rationale: Unmet Need
Rational Unmet Need Neutrolin® | ¥CorMedix Patients require a reliable vascular access (hemodialysis, chemotherapy, ICU, and TPN) Central venous catheters (CVC) are associated with two complications: = Thrombosis = Infection The current standard of care in many dialysis units is to use heparin only
Slide 6: Neutrolin Strategic Pillars
Neutrolin® Strategic Pillars
Slide 7: Neutrolin Strategic Pillars
Neutrolin® Strategic Pillars Key Activities: • Successful launch in Germany and Austria • Experienced sales team targets early adopters • Increase healthcare provider awareness • Negotiate Partner Arrangements • Position Neutrolin® strategically § Pricing § Understand payer reimbursement policies
Slide 8: EU Launch Strategy - On Track
EU Launch Strategy - On Track | @CorMedix |__| Currentand Planned Key Activities Planned Next Steps * On-going contacts with private dialysis units, * O1 ket hit hospitals, and KfH to understand their common Bepine meee Market : " Germany and Austria practice, unmet needs, and reimbursement Research
Slide 9: Neutrolin Strategic Pillars
Neutrolin® Strategic Pillars Key Activities: • Expansion into oncology, ICU, Total Parenteral Nutrition, and peritoneal dialysis fields • Submission of required data to TUV • Develop target list of physicians and expand the sales force
Slide 10: Neutrolin Strategic Pillars
Neutrolin® Strategic Pillars Key Activities: • Identify and prioritize key countries • Identify best sales partners in key countries § Screening/due diligence / deal negotiations conducted with country and regional specific advisors • Complete agreements • Monitor product positioning and coordinate
Slide 11: Neutrolin Strategic Pillars
Neutrolin® Strategic Pillars Potential Opportunity for Consideration: • U.S. FDA discussions (pre-IND meeting, timelines) • Clinical trial requirements by FDA § Patient population size § Duration • Clinical trial execution decision § Strategic partner § Go alone if sufficient internal funding
Slide 12: Business Development to Target Countries with High Catheter Use and Favorable Reimbursement
Business Development to Target Countries with High Catheter Use and Favorable Reimbursement • Major Countries: U.S., Japan, China, Brazil, Germany, Canada Source: Derived from USRDS, 2011, and Dialysis Outcomes and Practice Pattern Study (DOPPS) Annual Report 2010, and Canadian Institute for Health
Slide 13: Process in Place to Select Best Sales Partner
Process in Place to Select Best Sales Partner
Slide 14: atvanestoe cep cep str nt ape be teeny ey
2 atvanestoe cep cep str nt ape 2 be teeny ey Sabet Net {tanya Fae’ in oe ape ener oe yt cmp eon at i ea oe 7 nett id i rey Emr ob a CE SU Ritter demons tomy team man ee acne ml peng ame my eyes perpeons eb woddbe se poman ob pce feta ae me
Slide 15: Non-binding Term Sheet
ortedtx ne. Non-binding Term Sheet | ¥CorMedix CorMedix Neutrolin® Fee Score cceminc ane ence tertoriguem tena en 1 Drenden ey ng tambo tec re of eh + Daeretsntettcr on nm hpi ono pm om Why Neutrolin®? esa! vee ttc te titan eben nd rambo Ts ae eng {ccadincrom ims ogre mca nonin in ie ne = ori comin
Slide 16: CorMedix Sales Rep Training Guide
WCorMedix | ¥CorMedix CorMedix Sales Rep Training Guide Dh comet ego as aes eps th casos nh he cn-ae pki, mes ayer comune farther unanang te cet Ce tm ne en Tang pres on mons eter ssn nd moet he omen gee om Cortedix Market Research Discussion Guide eguing he Uso Turned, ae env Venous Catheter fo Vas
Slide 17: Large Worldwide Hemodialysis Opportunity
European Union Sales Partnerships: • 91,000 hemodialysis catheter patients • 28 countries U.S. Clinical Development Funding and Sales Partnerships • 104,000 hemodialysis catheter patients Asia/Middle East/North and South America Sales Partnerships • 106,000 hemodialysis catheter patients • China, Ja
Slide 18: Opportunity to Grow with Label Expansion into other Catheter Applications
European Union Sales Partnerships: • 145,600 catheter patients • 28 countries U.S. Clinical Development Funding and Sales Partnerships • 124,800 catheter patients Asia/Middle East/North and South America Sales Partnerships • 106,000 catheter patients • China, Japan, Korea, Saudi Arabia, Brazil, Cana
Slide 19: Significant Near Term Hemodialysis Opportunity in E.U.
Initially CorMedix will target the Hemodialysis market: • E.U. : 91,000 hemodialysis catheter patients Potential Hemodialysis Market Size in E.U. : USD $40 - $80 million Significant Near Term Hemodialysis Opportunity in E.U. These patients represent ~14.2 million HD sessions per year (91,000 HD cath
Slide 20: Even Greater Opportunity in the Long Term with Other Key Countries
Hemodialysis and Expanded Label market: • E.U.: 236,600 catheter patients • Other Key Countries: 212,000 catheter patients …..and Even Greater Opportunity in the Long Term with Other Key Countries and an Expanded Label Long Term Potential Market Size in E.U. and Other Key Countries for Hemodialysis
Slide 21: Option to Enter the United States with Strategic Partnerships or Internal Funding
U.S. Hemodialysis and Expanded Label market: • 228,800 catheter patients Option to Enter the United States with Strategic Partnerships or Internal Funding Long Term Potential Market Size in U.S. for Hemodialysis and Expanded Label: USD $140 - $270 million Top 5 Hemodialysis markets: U.S., Japan, Chi
Slide 22: IP Status Update
IP Status Update • Global Patent Estate - 17 issued patents provide protection through 2019-2025 § Freedom to Operate § Proprietary Ø Sodemann : A method of inhibiting or preventing infection and blood coagulation as a medical prosthetic device using a pharmaceutical composition comprising taurolidi
Slide 23: Neutrolin Strategic Pillars
Neutrolin® Strategic Pillars
Slide 24: Thank You!
Thank You! http://www.CorMedix.com/ NYSE MKT: CRMD August 2013